Tyrosine and aurora kinase inhibitors diminish transport function of multidrug resistance-associated protein (MRP) 4 and breast cancer resistance protein (BCRP)

Abstract

Tyrosine and aurora kinases are important effectors in signal transduction pathways that are often involved in aberrant cancer cell growth. Tyrosine (TKI) and aurora (AKI) kinase inhibitors are anti-cancer MRP4: alisertib, danusertib, erlotinib, lapatinib, neratinib, nilotinib, pazopanib, sorafenib, and tozasertib. The potentially clinically relevant inhibition of BCRP was much more extensive and included alisertib, barasertib, danusertib, enzastaurin, erlotinib, gefitinib, imatinib, neratinib, nilotinib, pazopanib, selumetinib, sorafenib, sunitinib, tozasertib, and vandetanib Keywords ABC transporters; transport inhibition ADMET & DMPK 4(4) (2016) 302-313TKIs and AKIs diminish transport of function of MRP4 and BCRP

Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins

“…This study revealed for the first time that sulfasalazine can be successful in producing significant reductions in the protein expression levels of p-NFκB, BCR/ABL, p-STAT-3, p-Akt and VEGF and cause a significant increase in caspase-3 expression, which is in line with other studies [40][41][42][43][44][45], which could be the result of the inhibition of NFκB as one possible pathway for the decrease in VEGF because p-NFκB is considered to be a potent transcription factor that controls the expression of many downstream proteins, such as BCR/ABL, p-STAT-3, p-Akt and VEGF. In addition, crosstalk between the NFκB and p-STAT-3 pathways was found.…”